A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy

NCT07752264 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Immune-mediated Necrotizing Myopathy

Interventions

DRUG: Equecabtagene Autoleucel Injection (Eque-cel)

Sponsor

Nanjing IASO Biotechnology Co., Ltd.